Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up
复制标题
DOI：
10.1093/annonc/mds224
复制
发表时间：
2012-10-01
影响因子：
50.5
通讯作者：
Rougier, P.
中科院分区：
文献类型：
--
作者：
Seufferlein, T.;Bachet, J. B.;Rougier, P.
在欧洲，胰腺癌是第七大常见癌症，约占男性癌症的2.8%和女性癌症的3.2%。它是癌症相关死亡的第五大原因，估计每年有70，000人死亡，预计在适当的时候将成为欧盟男女癌症死亡的第四大原因[1，2]。男性的年平均发病率估计为11.6/100 000，从4.7（塞浦路斯）到17.2（匈牙利）不等。男性死亡率为每年35，000例。估计女性平均发病率为每10万人8.1例，范围从2.1例（塞浦路斯）到11.4例（芬兰）。女性的死亡率也是每年35000例[3]。发病率随着年龄的增长而增加，大多数病例在65岁以上被诊断出来。吸烟、肥胖和饮食因素（如大量食用加工肉类）会增加胰腺癌的风险[4，5]（II）。胰腺癌的预后仍然很差。根据EUROCARE 4研究，欧洲的总体1年生存率从马耳他的11.1%到比利时的28.3%不等;> 95%的受影响者死于这种疾病。死亡率高是由于诊断晚，早期转移，化疗和放疗效果差。可切除胰腺癌患者的生存率通过辅助化疗得到适度改善。最近，通过新的联合化疗可以实现转移性环境中生存率的一些改善（见下文）。
In Europe, cancer of the pancreas is the seventh most frequent cancer, accounting for some 2.8% of cancer in men and 3.2% in women. It is the fifth leading cause of cancer-related death with∼ 70 000 estimated deaths each year and predicted to become the fourth cause of cancer death in both sexes in due course in the European Union [1, 2]. In men, the estimated annual average incidence rate is 11.6 per 100 000 ranging from 4.7 (Cyprus) to 17.2 (Hungary). Mortality in men is∼ 35 000 cases per year. The estimated average incidence rate in women is 8.1 per 100 000 ranging from 2.1 (Cyprus) to 11.4 (Finland). Mortality in women is also∼ 35 000 cases per year [3]. Incidence increases with age and the majority of cases are diagnosed above the age of 65. Smoking, obesity and dietary factors such as high consumption of processed meat increase the risk for pancreatic cancer [4, 5](II).Pancreatic cancer still has a dismal prognosis. According to the EUROCARE 4 study, the overall 1-year survival rate in Europe ranges from∼ 11% in Malta to 28.3% in Belgium;> 95% of those affected die of the disease. The high mortality rate is due to late diagnosis, early metastasis and poor response to chemo-and radiotherapy in most cases. Moderate improvement in survival in resectable pancreatic cancer has been achieved by adjuvant chemotherapy. Recently, some improvement in survival in the metastatic setting could be achieved by novel combination chemotherapy (see below).